Dillon & Associates Inc. decreased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 4.0% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 452 shares of the company’s stock after selling 19 shares during the period. Dillon & Associates Inc.’s holdings […]